Analyst consensus rating
Immuneering Analyst Rating: Strong Buy
IMRX is rated Strong Buy by 7 analysts with a $17.57 target. As of 2026-08-26.
Direct answer
Immuneering's consensus rating is Strong Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.57.
Forecast evidence checked August 26, 2026.
Get free Immuneering email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $5.23
- Average price target
- $17.57
- High price target
- $30.00
- Low price target
- $12.00
- Low target gap
- +129.4%
- Target upside
- +236%
- High target gap
- +473.6%
- Target range width
- 344.2%
- Consensus rating
- Strong Buy
- Analysts
- 7
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Immuneering?
Immuneering has a verified Strong Buy consensus. The same dataset has an average price target of $17.57.
How far are Immuneering's low and high targets from the recorded price?
The low target implies +129.4%, while the high target implies +473.6%.
How many analysts are included in Immuneering's consensus?
The verified consensus includes 7 analysts.
How is Immuneering's target upside or downside calculated?
The average target of $17.57 is divided by the recorded price of $5.23, then one is subtracted to produce +236%. This does not guarantee a future return.
When was Immuneering's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.